The projected fair value for Moderna is US$151 based on 2 Stage Free Cash Flow to Equity Current share price of US$79.01 suggests Moderna is potentially 48% undervalued Analyst price target for MRNA is US$140 which is 7.6% below our fair value estimate Does the November share price for Moderna,
美國知名新冠疫苗生產商Moderna(MRNA.US)當地時間周二表示，該公司于本月開始建造在中國的首個生產mRNA藥物的工廠。據了解，Moderna所生產的新冠病毒疫苗尚未在中國市場獲...
From pandemic fatigue to vaccine fatigue — Americans are proving slow to follow the CDC’s advice to get a COVID-19 booster shot this fall. On Sept. 12, the CDC recommended that everyone six months and older should get an updated COVID-19 vaccine to protect against the potentially serious outcomes
Ron Baron (Trades, Portfolio), the esteemed founder of Baron Capital Management and a seasoned investor known for his long-term growth strategy, has made notable changes to his portfolio in the third quarter of 2023. With a keen eye for small to mid-size growth companies, Baron's investment philoso
Warning! GuruFocus has detected 5 Warning Signs with MELI. Baillie Gifford (Trades, Portfolio), a century-old investment management partnership, is renowned for its commitment to long-term, bottom-up investing and fundamental analysis. The firm's recent 13F filing for Q3 2023 reveals strategic adj
Salesforce bounced off the bottom of the Dow ranking and soared to the top.
新冠疫苗製造商 Novavax (NVAX-US) 周四 (9 日) 公布的第 3 季營收高於預期，得益於美國政府為幫助支付臨床試驗費用提供的撥款，並表示準備明年進一步削減成本。
Vaccine maker reins in full-year sales outlook, looks to expand cost-cutting program
Salesforce bounced off the bottom of the Dow ranking and soared to the top
Personalis, Inc. (NASDAQ:PSNL) Q3 2023 Earnings Call Transcript November 7, 2023 Personalis, Inc. beats earnings expectations. Reported EPS is $-0.48, expectations were $-0.54. Operator: Good afternoon and welcome to Personalis Third Quarter 2023 Earnings Conference Call. All participants will be
